ChromaDex Corporation (CDXC) CEO Rob Fried on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/04/21
Analysts Estimate ChromaDex (CDXC) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 10/27/21
ChromaDex Shares Findings from First Clinical Study on Nicotinamide Riboside (NR) in Children, Highlighting Improvements for Prematurely Aging Patients with Ataxia-Telangiectasia (AT)Business Wire • 10/18/21
ChromaDex to Report Third Quarter 2021 Financial Results on Wednesday, Nov. 3, 2021Business Wire • 10/13/21
ChromaDex Comments on Jury Award Against Elysium Health and Reiterates Plans for GrowthBusiness Wire • 10/01/21
ChromaDex Partners with Sinopharm Xingsha for Cross-Border Sales of Tru Niagen® into Mainland ChinaBusiness Wire • 09/29/21
ChromaDex Shares Preclinical Research Findings and Scientific Initiations from the ChromaDex External Research Program (CERP™)Business Wire • 09/20/21
ChromaDex Continues to Defend Strong Intellectual Property Portfolio and Plans to Appeal Judge's Ruling in Patent Infringement LawsuitBusiness Wire • 09/15/21
ChromaDex Corporation (CDXC) CEO Rob Fried on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/04/21
ChromaDex to Report Second Quarter 2021 Financial Results on Tuesday, August 3, 2021Business Wire • 07/20/21
CHROMADEX'S HEALTHY AGING PRODUCTS GAIN NEW TRACTION WITH FOUR HUGE DISTRIBUTION AGREEMENTS INCLUDING WALMARTBenzinga • 06/16/21
ChromaDex Shares Research Findings from the ChromaDex External Research Program (CERP™)Business Wire • 06/16/21
ChromaDex and Walmart Launch Tru Niagen® in 3,800 Walmart Stores Across the United StatesBusiness Wire • 06/07/21